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Abstract
Background: Sleep disturbance is common in dementia and often treated with Z-drugs (zopiclone, zaleplon, and
zolpidem). While some observational studies suggest that Z-drugs are associated with adverse events such as falls
and fracture risks in older people, this has not been studied in dementia.
Methods: We used data from 27,090 patients diagnosed with dementia between January 2000 and March 2016
from the Clinical Practice Research Datalink linked to Hospital Episodes Statistics data in England. We compared
adverse events for 3532 patients newly prescribed Z-drugs by time-varying dosage to (1) 1833 non-sedative-users
with sleep disturbance; (2) 10,214 non-sedative-users with proximal GP consultation matched on age, sex, and
antipsychotic use; and (3) 5172 patients newly prescribed benzodiazepines. We defined higher dose Z-drugs and
benzodiazepines as prescriptions equivalent to ≥ 7.5 mg zopiclone or > 5 mg diazepam daily. Cox regression was
used to estimate hazard ratios (HRs) for incident fracture, hip fracture, fall, mortality, acute bacterial infection,
ischaemic stroke/transient ischaemic attack, and venous thromboembolism over a 2-year follow-up, adjusted for
demographic- and health-related covariates.
Results: The mean (SD) age of patients was 83 (7.7) years, and 16,802 (62%) were women. Of 3532 patients
prescribed Z-drugs, 584 (17%) were initiated at higher doses. For patients prescribed higher dose Z-drugs relative to
non-users with sleep disturbance, the HRs (95% confidence interval) for fractures, hip fractures, falls, and ischaemic
stroke were 1.67 (1.13–2.46), 1.96 (1.16–3.31), 1.33 (1.06–1.66), and 1.88 (1.14–3.10), respectively. We observed similar
associations when compared to non-sedative-users with proximal GP consultation. Minimal or inconsistent excess
risks were observed at ≤ 3.75 mg zopiclone or equivalent daily, and for mortality, infection, and venous
thromboembolism. We observed no differences in adverse events for Z-drugs compared to benzodiazepines,
except lower mortality rates with Z-drugs (HR [95% confidence interval] of 0.73 [0.64–0.83]).
Conclusions: Higher dose Z-drug use in dementia is associated with increased fracture and stroke risks, similar or
greater to that for higher dose benzodiazepines. Higher dose Z-drugs should be avoided, if possible, in people
living with dementia, and non-pharmacological alternatives preferentially considered. Prescriptions for higher dose
Z-drugs in dementia should be regularly reviewed.
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Background
Around 60% of people living with dementia (PlwD) are
affected by sleep disturbance [1, 2], including insomnia,
fragmented night-time sleep, night-time wandering, or
excessive day sleep [3]. Sleep disturbance affects the
quality of life of PlwD and their informal carers and
often leads to care home admission [4].
Benzodiazepines are frequently used for insomnia in
PlwD and act by binding to gamma-aminobutyric acid,
an inhibitory neurotransmitter [5]. Benzodiazepines are
associated with a range of adverse side-effects including
cognitive impairment, daytime sedation, tolerance, de-
pendence, and falls [6–9]. Z-drugs (zaleplon, zopiclone,
eszopiclone, and zolpidem), a class of non-
benzodiazepine gamma-aminobutyric acid agonists, have
shorter half-lives and were originally believed to be safer
than benzodiazepines, but their adverse effects are in-
creasingly recognised [10, 11]. Observational studies re-
port Z-drugs are associated with increased risks of falls,
fractures, stroke, mortality, and infection in older adults
[12–16]. However, these studies are generally subject to
residual confounding by sleep disturbance and comor-
bidity. Studies have also not typically examined how the
timing and dosages of Z-drugs might modify risk. More
importantly, the adverse effects of Z-drugs have rarely
been studied in PlwD, where these side-effects can be
particularly catastrophic [17]. A recent Cochrane review
found insufficient evidence to guide drug treatment of
sleep problems in dementia [18], despite wide-scale pre-
scribing [19]. In addition, the effectiveness of Z-drugs to
improve sleep in older people is uncertain and consid-
ered limited [11], with cognitive behaviour therapy dem-
onstrated to be more effective at managing insomnia
than zopiclone in older adults [20].
We examined the association between first Z-drug
prescription and subsequent risk of falls, fractures, mor-
tality, infection, ischaemic stroke, and venous thrombo-
embolism in PlwD. To reduce confounding, we
compared Z-drug users with (1) non-users with sleep
disturbance, (2) non-users with a proximal GP consult-
ation, and (3) new benzodiazepine users.
Methods
Study design
We performed a series of cohort studies, using data from
the Clinical Practice Research Datalink (CPRD) linked to
Hospital Episode Statistics (HES), Office for National
Statistics (ONS) mortality data, and Index of Multiple
Deprivation data in England. CPRD collates all diagno-
ses, referrals, and prescribing records for over 11.3 mil-
lion patients broadly representative of the UK
population [21]. Diagnosis information is electronically
entered as UK Read codes [22]. HES records all diagno-
ses made during a hospital admission (coded using the
International classification of diseases 10th revision
[ICD-10]) and demographic information [23], and ONS
provides date and cause of death (ICD-10 coded) [24].
The Index of Multiple Deprivation combines a number
of indicators of housing, employment, income, educa-
tion, and environment at the general practice level [25].
CPRD obtained ethical approval from a National Re-
search Ethics Service Committee, allowing researchers to
access anonymised data for observational studies upon
approval from an Independent Scientific Advisory
Committee.
Study population
We defined dementia patients by record of a dementia
diagnosis in CPRD (codes in Additional file 1) or HES
(ICD-10 F00-F03, G30, G31.0 or G31.1) or prescription
of a cognitive enhancer (i.e. memantine, donepezil, rivas-
tigmine, or galantamine), occurring after January 2000
when aged ≥ 55 years. We excluded patients with < 3
months of ‘up-to-standard’ (research quality) data or
with severe mental illness or Down syndrome before de-
mentia diagnosis (codes in Additional file 1) [21].
Exposures
Our primary exposure was new prescription of Z-drugs.
We considered three comparator groups to reduce con-
founding [26]. The primary comparator was record of
sleep disturbance without sedative-hypnotic prescription.
Secondary comparators were (a) non-users at a proximal
GP consultation and (b) new benzodiazepine users. To
facilitate these comparisons, three main cohorts were
constructed, with their index date as the first date after
dementia diagnosis of (a) prescription for a Z-drug
(World Health Organization’s Anatomic Therapeutic
Classification [ATC] system category N05CF), (b) pre-
scription of any benzodiazepine (ATC N05BA or
N05CD except midazolam injection), and (c) code for
sleep disturbance (codes in Additional file 1) but without
a concurrent sedative-hypnotic (ATC N05C or N05BA)
prescription.
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Two additional cohorts were created by matching the
Z-drug and BZD cohorts on age, sex, and antipsychotic
use, to non-users (not prescribed sedative-hypnotics)
with proximal GP consultation. We matched three non-
users to each Z-drug or benzodiazepine user, without re-
placement, and assigned an index date as the closest GP
consultation within 1 month of the corresponding Z-
drug or benzodiazepine index date. Patients could be
members of different cohorts over time.
Exclusion criteria for all cohorts were (1) < 12months
data history; (2) sedative-hypnotic prescription in the
last 12 months; (3) prior diagnosis of sleep apnoea,
sleep-related respiratory failure, or alcohol abuse (codes
in Additional file 1); (4) prescription of multiple
sedative-hypnotics; and (5) newly prescribed antipsy-
chotics or low-dose tricyclic or related antidepressants
(≤ 25mg amitriptyline or ≤ 50mg trazodone per day).
We additionally performed a separate validation study
on the accuracy of our patient selection (details in Add-
itional file 2). In summary, GP practices confirmed de-
mentia diagnoses in 96% of cases; however, uncertainty
was raised regarding the accuracy of those identified
with sleep disturbance.
To test dose-response relationships, we determined
the number of daily defined doses (DDDs) of Z-drugs
and benzodiazepines at each prescription. The DDD is
the assumed average maintenance dose per day for a
drug based on its main indication in adults. We used
DDD values from the World Health Organization’s Col-
laborating Centre for Drug Statistics Methodology
(www.whocc.no/atc_ddd_index), where the DDDs for
zopiclone, zolpidem, and zaleplon are 7.5 mg, 10 mg, and
10mg per day, respectively. The British National Formu-
lary recommends these daily doses for adults with in-
somnia, but to halve them for elderly patients. Missing
dosing frequency data was assumed once daily, except
diazepam where we applied the most common frequency
for the product and quantity prescribed among the
complete prescription data.
Outcomes
The selected outcomes were identified from previous
studies or were priorities identified by our Patient and
Public Involvement (PPI) group members or by an advis-
ory group of healthcare professionals established to sup-
port this project. The main outcomes were, in order of
importance: (1) incident (a) fracture in any location, (b)
hip fracture, and (c) forearm/wrist/hand fracture; (2) in-
cident fall; (3) mortality; (4) acute bacterial infection; (5)
ischaemic stroke/transient ischaemic attack; and (6) ven-
ous thromboembolism. These were identified via first
mention of a relevant Read code in CPRD or ICD-10
code in HES or ONS (codes in Additional file 3). We
also examined further healthcare utilisation outcomes:
(7) number of (a) hospital admissions and (b) GP con-
sultations and (8) new prescription of (a) antipsychotics,
(b) antidepressants, and (c) antibiotics.
Covariates
We considered as potential confounders variables sus-
pected to be linked to dementia, sleep disturbance,
benzodiazepine or Z-drug use, or the outcomes exam-
ined. They were measured on the index date and cov-
ered domains of demographics, health behaviours,
dementia subtype, proxies for dementia severity, proxies
for sleep disturbance severity, comorbidities, recent
medical history (e.g. GP consultations, hospital admis-
sions, falls, fractures, infections, immunisations, body
mass index [BMI], systolic blood pressure), and concur-
rent prescriptions (details in Additional file 4).
Statistical analysis
The primary analysis estimated the association between
new prescription of sleep disturbance medication and in-
cidence of each outcome, compared to other groups. We
followed patients until the earliest of death, leaving the
GP practice, last data extraction, new sedative-hypnotic
or antipsychotic prescription, 2 years post-index date, or
31 March 2016. Z-drug and benzodiazepine new users
were also censored 90 days following their last Z-drug/
benzodiazepine prescription. Matched patients were
additionally censored at the censoring date of their cor-
responding case. Specific exclusion criteria applied at the
index date to reduce the chance of repeated coding of
the same event are described in Additional file 5 table
S1.
Cox proportional hazards regression was used for bin-
ary outcomes. We used robust standard errors to ac-
count for the correlation due to repeat measurements in
some patients [27]. The proportional hazards assump-
tion was checked using Schoenfeld residuals [28]. Nega-
tive binomial regression was used to model the number
of hospital admissions and GP consultations. Estimates
were adjusted for age and sex and all covariates in Add-
itional file 4. Age, BMI, systolic blood pressure, duration
since dementia diagnosis, index date, and number of
prior GP consultations were modelled using restricted
cubic splines (with five knots) to allow non-linear effects
[29]. We included an interaction between sex and BMI,
due to known sex differences in the relationship between
BMI and fracture risk [30]. Absolute risk differences of
adverse events and numbers needed to harm (NNH)
were estimated using standard formulae for time to
event analysis [31].
We examined the average daily Z-drug dose over
follow-up, but in post hoc secondary analysis, to reflect
changes in dose, we examined time-varying daily DDDs.
In the sensitivity analysis, we excluded those with record
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of > 6 h sleep per night from the sleep-disturbance com-
parator group (see validation study in Additional file 2
for more detail). This was to increase the chance that
the sleep-disturbance group had more comparable in-
somnia to the Z-drug group. Finally, in the comparison
of Z-drug to benzodiazepine new users, we restricted to
benzodiazepines likely prescribed for sleep disturbance
(loprazolam, lormetazepam, nitrazepam, temazepam, or
other benzodiazepines with dosing instructions to take
only at night or with a concurrent record of sleep
disturbance).
Multiple imputation by chained equations was used to
impute missing values of BMI, smoking, alcohol use,
residence, ethnicity, and blood pressure (see Add-
itional file 4 for details) [32]. To account for multiple
outcomes tested, we used the Benjamini-Hochberg pro-
cedure to control the false discovery rate at < 5% for
each analysis [33]. Stata version 15.1 was used
throughout.
Results
There were 51,117 eligible dementia patients with ≥ 12-
month data history in the linked CPRD-HES database
(Additional file 5 figure S1). Of these, 3532 and 5172 pa-
tients were newly prescribed Z-drugs or benzodiaze-
pines, respectively, and met our inclusion criteria. Z-
drug and benzodiazepine new users were matched to 10,
214 and 15,174 non-users, respectively. Finally, 1833 de-
mentia patients had recorded sleep disturbance, but
without prescription of sedative-hypnotics.
Patient characteristics
The mean (SD) age of patients at index date was 83 (7.7)
years, and 16,802 (62%) were women. Patients were reg-
istered with their GP for a median (IQR) of 19 (11–32)
years and diagnosed with dementia for a median (IQR)
of 12 (4–25) months.
The patient cohorts were similar across measured
characteristics (Table 1 with missing data described in
Additional file 5 table S2). Recent hospital admissions
were more likely among Z-drug users. Concurrent anti-
psychotics and antidepressants and previous benzodi-
azepine or Z-drug use was more likely among
benzodiazepine and Z-drug users. Benzodiazepine users
more frequently lived in care homes and had agitation/
psychosis and anxiety and dementia for longer. Those
with sleep disturbance (no sedative-hypnotics) were
more likely from a deprived neighbourhood, consume al-
cohol, and have urinary incontinence and insomnia his-
tory before dementia. Finally, the non-users with
proximal GP consultation had more recent GP consulta-
tions and fewer recent falls and fractures.
Of 3532 patients prescribed Z-drugs, 3358 (95%) were
prescribed zopiclone, with 2801 (83%) prescribed 3.75
mg daily on the index date. For 598 (17%), the prescrip-
tion instructions were ‘pro re nata’ (PRN/as needed). Of
5172 patients prescribed benzodiazepines, the most
common were diazepam (n = 2077, 40%), lorazepam
(n = 1669, 32%), and temazepam (n = 1168, 23%).
Patients were followed up for a median (IQR) of 3.5
(3.0–10.3) months and mainly censored due to no fur-
ther Z-drug or benzodiazepine prescriptions. See Add-
itional file 5 table S3 for initial and follow-up doses.
Falls and fractures
We estimated HRs (95% CI) of 1.32 (0.99–1.75) and
1.34 (1.08–1.67) for Z-drugs and fracture compared
to sleep disturbance (without sedative-hypnotics) and
non-use with proximal GP consultation, respectively
(Table 2). For hip fracture, the HRs (95% CI) were
1.38 (0.92–2.06) and 1.59 (1.15–2.19) for Z-drugs
compared to sleep disturbance and non-use with
proximal GP consultation, respectively. Z-drug use
was associated with increased falls compared to non-
use with proximal GP consultation (HR 1.43, 95% CI
1.26–1.62), but not compared to sleep disturbance
(HR 1.02, 95% CI 0.87–1.21). New benzodiazepine use
was associated with increased fractures and falls com-
pared to non-use with proximal GP consultation, but
the HR (95% CI) for hip fractures was 1.17 (0.87–
1.57) (Additional file 5 table S4). There were no large
differences in fall and fracture rates between new Z-
drug and benzodiazepine users (Table 2).
There was evidence of differing associations with the
outcomes according to the prescribed daily dose of Z-
drugs or benzodiazepines (Table 3 and Additional file 5
table S5). Compared to sleep disturbance without
sedative-hypnotics, the adjusted HRs (95% CI) for frac-
tures, hip fractures, and falls for Z-drug prescriptions
equivalent to ≥ 7.5 mg zopiclone daily were 1.67 (1.13–
2.46), 1.96 (1.16–3.31), and 1.33 (1.06–1.66), respect-
ively. The adjusted HRs (95% CI) for Z-drug prescrip-
tions equivalent to ≤ 3.75 mg zopiclone daily and
fractures, hip fractures, and falls were 1.22 (0.90–1.66),
1.21 (0.78–1.90), and 0.95 (0.80–1.13), respectively. Simi-
lar associations were observed when compared to non-
users with proximal GP consultation.
Absolute risks
The use of zopiclone at ≥ 7.5 mg or equivalent is associ-
ated with absolute annual risks of fracture of 12.4%
(compared to 7.6% in the sleep disturbance cohort). For
hip fracture, the corresponding figures are 6.6% annual
risk associated with zopiclone at ≥ 7.5 mg or equivalent
compared to 3.4%. This is equivalent to NNH of 21 and
32, and extra cases per 1000 treated of 48 and 32 for
fractures and hip fractures, respectively.
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Table 1 Characteristics of patients with dementia prescribed Z-drugs and benzodiazepines and comparison cohorts
Z-drug
(n = 3532)
Sleep disturbance, no sedative-hypnotic
(n = 1833)
No Z-drug,
proximal GP
consultation
(n = 10,214)
Benzodiazepine
(n = 5172)
No benzodiazepine,
proximal GP
consultation
(n = 15,174)
Characteristic n % n % n % n % n %
Women 2087 59% 1145 62% 6074 59% 3222 62% 9491 63%
Age, yearsa 82.9 7.7 83.1 7.1 83.1 7.5 82.5 7.8 82.6 7.8
White ethnicityb 3072 87% 1539 84% 8816 86% 4470 86% 13,042 86%
Care homeb 892 25% 434 24% 2108 21% 1509 29% 2979 20%
Lives aloneb 760 22% 545 30% 2848 28% 993 19% 4785 32%
GP practice area IMD quintilea 3.2 1.4 3.4 1.4 3.1 1.4 3.2 1.4 3.1 1.4
Current smokerb 312 9% 142 8% 722 7% 355 7% 1124 7%
Ex-smokerb 765 22% 428 23% 2226 22% 1163 22% 3322 22%
Alcohol drinkerb 715 20% 489 27% 2142 21% 1127 22% 3297 22%
Body mass indexa,b 24.9 4.9 24.5 4.6 24.9 4.8 24.5 4.8 24.8 4.9
Systolic blood pressurea,b 133.5 19.0 133.9 18.8 134.3 19.1 133.6 18.9 134.5 18.8
Dementia
Months since dementia
diagnosisc
11.4 3.6–
26.2
11.0 3.8–24.1 13.5 5.2–
27.4
15.6 5.1–32.4 10.3 3.7–22.0
Dementia subtype
Alzheimer’s disease 1355 38% 746 41% 4224 41% 2140 41% 6612 44%
Vascular dementia 940 27% 487 27% 2773 27% 1375 27% 4046 27%
Other/mixed dementia 409 12% 192 10% 1013 10% 600 12% 1377 9%
Unspecified dementia 828 23% 403 22% 2184 21% 1057 20% 3139 21%
Agitation/psychosis history 619 18% 409 22% 1261 12% 1363 26% 1341 9%
End of life care 197 6% 77 4% 564 6% 416 8% 726 5%
Sleep disturbance
Sleep disturbance pre-
dementia
825 23% 615 34% 1982 19% 1064 21% 2918 19%
History of benzodiazepine
use
869 25% 222 12% 1376 13% 982 19% 2009 13%
History of Z-drug use 304 9% 113 6% 597 6% 481 9% 852 6%
Medical history in the past year
Falls 1003 28% 542 30% 2165 21% 1241 24% 3359 22%
Fractures 360 10% 131 7% 657 6% 409 8% 1071 7%
Dizziness/unsteadiness 214 6% 127 7% 652 6% 294 6% 817 5%
Faints/syncope 184 5% 120 7% 533 5% 357 7% 712 5%
Urinary tract infection/acute
LRTI
928 26% 423 23% 2054 20% 1242 24% 3114 21%
Influenza vaccination 2480 70% 1340 73% 7747 76% 3739 72% 11,350 75%
Pneumonia vaccination 166 5% 103 6% 506 5% 234 5% 773 5%
Physician consultationsa 12.5 10.3 11.2 9.4 14.9 12.7 12.9 10.7 13.7 12.0
Hospital admissionsa 1.3 3.0 1.0 2.2 0.9 1.6 1.1 1.9 0.9 2.3
Comorbidities
Depression 894 25% 493 27% 2633 26% 1512 29% 3723 25%
Depression symptoms 692 20% 368 20% 1898 19% 1175 23% 2804 18%
Anxiety 576 16% 311 17% 1648 16% 1204 23% 2451 16%
Anxiety symptoms 446 13% 261 14% 1181 12% 877 17% 1751 12%
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Table 1 Characteristics of patients with dementia prescribed Z-drugs and benzodiazepines and comparison cohorts (Continued)
Z-drug
(n = 3532)
Sleep disturbance, no sedative-hypnotic
(n = 1833)
No Z-drug,
proximal GP
consultation
(n = 10,214)
Benzodiazepine
(n = 5172)
No benzodiazepine,
proximal GP
consultation
(n = 15,174)
Characteristic n % n % n % n % n %
Parkinson’s disease 208 6% 109 6% 530 5% 290 6% 723 5%
Urinary incontinence 520 15% 465 25% 1640 16% 841 16% 2273 15%
Benign prostatic hyperplasia 361 10% 175 10% 1075 11% 487 9% 1474 10%
Asthma 366 10% 165 9% 1056 10% 517 10% 1590 10%
Cancer 743 21% 313 17% 2114 21% 1002 19% 3074 20%
COPD 266 8% 147 8% 782 8% 369 7% 1209 8%
Osteoporosis 417 12% 215 12% 1224 12% 581 11% 1885 12%
Other muscleroskeletal
conditions
448 13% 248 14% 1395 14% 664 13% 2036 13%
Osteoarthritis/rheumatoid
arthritis
1426 40% 756 41% 3980 39% 2063 40% 5906 39%
Other joint conditions 2901 82% 1537 84% 8463 83% 4293 83% 12,615 83%
Headache/migraine 720 20% 363 20% 2020 20% 1101 21% 2955 19%
Back/neck pain 1959 55% 1009 55% 5640 55% 2910 56% 8380 55%
Age-related macular
degeneration
189 5% 115 6% 648 6% 348 7% 923 6%
Cataract 992 28% 547 30% 2940 29% 1400 27% 4284 28%
Glaucoma 356 10% 186 10% 1011 10% 445 9% 1459 10%
Retinal disorder 295 8% 138 8% 944 9% 415 8% 1390 9%
Diabetes 531 15% 245 13% 1712 17% 718 14% 2483 16%
Hyperlipidaemia 470 13% 269 15% 1443 14% 754 15% 2152 14%
Hypertension 1822 52% 1006 55% 5736 56% 2762 53% 8521 56%
Stroke/transient ischaemic
attack
783 22% 397 22% 2177 21% 1091 21% 3022 20%
Myocardial infarction 310 9% 172 9% 909 9% 433 8% 1307 9%
Heart failure 314 9% 182 10% 988 10% 444 9% 1350 9%
Atrial fibrillation 528 15% 260 14% 1666 16% 775 15% 2365 16%
Angina 532 15% 308 17% 1646 16% 811 16% 2263 15%
Venous thromboembolism 236 7% 123 7% 737 7% 341 7% 1029 7%
Prescriptions in the last 90 days
Anticholinesterase/
memantine
850 24% 385 21% 2417 24% 1237 24% 3662 24%
Antipsychotic 811 23% 371 20% 1586 16% 1125 22% 851 6%
SSRI antidepressant 763 22% 352 19% 1855 18% 1174 23% 2616 17%
Tricyclic antidepressant 363 10% 192 10% 835 8% 596 12% 1748 12%
Other antidepressant 294 8% 153 8% 575 6% 483 9% 771 5%
Antiepileptic 241 7% 110 6% 610 6% 424 8% 825 5%
Analgesic 1730 49% 808 44% 4107 40% 2338 45% 5805 38%
Inhaled corticosteroid 191 5% 96 5% 507 5% 196 4% 742 5%
Lipid regulating medication 1217 34% 630 34% 3492 34% 1644 32% 5324 35%
Diuretic 1188 34% 633 35% 3322 33% 1456 28% 4779 31%
Beta blocker 645 18% 328 18% 1907 19% 850 16% 2771 18%
ACE inhibitor 709 20% 379 21% 2222 22% 991 19% 3357 22%
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Mortality, infection, and cardiovascular outcomes
Although Z-drug use was associated with greater mortal-
ity compared to those with sleep disturbance (HR 1.38,
95% CI 1.14–1.66), there was no strong evidence of ex-
cess risk compared to non-users with a proximal GP
consultation (HR 1.08, 95% CI 0.94–1.23) (Table 2). Fur-
ther, the associations with mortality seemed unrelated to
dose (Table 3). Z-drug prescription was associated with
less mortality than benzodiazepines (HR 0.73, 95% CI
0.64–0.83).
We did not detect any strong associations between
new Z-drug prescription and greater infection or venous
thromboembolism rates, compared either to the non-
users or to the benzodiazepine users.
When examining new Z-drug prescription overall, we
did not detect strong associations with incident stroke
rates (HR 1.14 [95% CI 0.86–1.50], compared to non-
users with proximal GP consultation). However, higher
dose (≥ 7.5 mg zopiclone or equivalent) Z-drugs were as-
sociated with more ischaemic strokes (HR 1.88 [95% CI
1.14–3.10] and 1.90 [1.30–2.79] compared to sleep dis-
turbance and non-users with proximal GP consultation).
The association for higher dose Z-drugs appeared
greater than that for higher dose (> 5 mg diazepam or
equivalent) benzodiazepine use, with a HR (95% CI) for
higher dose benzodiazepine and stroke of 1.37 (0.91–
2.08) compared to non-use with proximal GP consult-
ation (Additional file 5 table S5).
Absolute risks
The use of zopiclone at ≥ 7.5 mg or equivalent is associ-
ated with absolute annual risks of stroke of 8.1%
(compared to 4.4% in the sleep disturbance cohort). This
is equivalent to an NNH of 27 and 37 extra cases per
1000 treated.
Additional medication and healthcare utilisation
The adjusted rate ratios (95% CI) for hospital visits for
Z-drug users were 1.26 (1.13–1.40), compared to sleep
disturbance, and 1.17 (1.07–1.27), compared to non-use
with proximal GP consultation. The rates between Z-
drugs and benzodiazepines were similar. For GP consul-
tations, the corresponding rate ratios were 1.17 (1.12–
1.23) and 1.07 (1.04–1.11), respectively. However, when
analysed by time-varying prescribed dose, more frequent
hospital admissions and GP consultations were generally
only observed for higher dose Z-drugs (Table 5) and
higher dose benzodiazepines (Additional file 5 table S6).
Z-drug users were more likely prescribed a new anti-
psychotic (HR 2.37, 95% CI 1.84–3.04) or antidepressant
(HR 2.32, 95% CI 1.65–3.25) during follow-up compared
to non-users with sleep disturbance (Table 4). There was
a small increase in antibiotic prescribing subsequent to
new Z-drug prescription compared to non-users with
proximal GP consultation (HR 1.19, 95% CI 1.08–1.30).
Rates of new prescribing were generally similar post-Z-
drug prescription to post-benzodiazepine prescription
and were greater with increasing Z-drug dose (Table 5).
Additional analyses
Similar associations to those for time-varying pre-
scribed dose were observed when analysing the
(non-time-varying) average number of doses pre-
scribed over the exposure period (Additional file 5
Table 1 Characteristics of patients with dementia prescribed Z-drugs and benzodiazepines and comparison cohorts (Continued)
Z-drug
(n = 3532)
Sleep disturbance, no sedative-hypnotic
(n = 1833)
No Z-drug,
proximal GP
consultation
(n = 10,214)
Benzodiazepine
(n = 5172)
No benzodiazepine,
proximal GP
consultation
(n = 15,174)
Characteristic n % n % n % n % n %
Angiotensin II receptor
antagonist
235 7% 124 7% 724 7% 330 6% 1123 7%
Calcium channel blocker 643 18% 339 18% 1947 19% 849 16% 2980 20%
Anticoagulant 204 6% 103 6% 739 7% 295 6% 1056 7%
Antiplatelet 1603 45% 878 48% 4390 43% 2171 42% 6439 42%
Cardiac glycoside 281 8% 155 8% 768 8% 345 7% 1032 7%
NSAID 352 10% 156 9% 815 8% 468 9% 1206 8%
Bisphosphonate 375 11% 194 11% 1074 11% 477 9% 1618 11%
Calcium/vitamin D 677 19% 377 21% 1854 18% 888 17% 2754 18%
Antibiotic (in last 30 days) 1098 31% 567 31% 2590 25% 1370 26% 3640 24%
Abbreviations: ACE angiotensin-converting enzyme, COPD chronic obstructive pulmonary disease, IMD Index of Multiple Deprivation, GP general practitioner, LRTI
lower respiratory tract infection, NSAID nonsteroidal anti-inflammatory drug, SSRI selective serotonin reuptake inhibitor
aMean (standard deviation)
bCharacteristic contains missing data as described in Additional file 5 table S2
cMedian (inter-quartile range)
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table S7-S8). In the sensitivity analysis using a com-
parator of those with sleep disturbance and no asso-
ciated mention of > 6 h sleep, associations for Z-drug
use were generally slightly reduced (Additional file 5
tables S9-S10). Finally, associations for Z-drug use
compared to the 1601 patients prescribed benzodiaz-
epines for sleep disturbance were very similar to
when comparing to any benzodiazepine (Add-
itional file 5, table S11).
Discussion
We found evidence of increased risks of falls, fractures,
and ischaemic stroke in people with dementia prescribed
Z-drugs at higher doses. The associations observed were
similar or greater in magnitude to those for higher dose
benzodiazepine prescription. One in six Z-drug prescrip-
tions were commenced at higher doses of equivalent to
7.5 mg zopiclone daily or greater. We did not detect any
consistent or clinically significant increased risks of
Table 2 Adjusted hazard ratios for new Z-drug prescription and adverse events for people with dementia
Outcome Comparator
Z-drug
(n = 3532)
Sleep disturbance, no
sedative-hypnotic (n = 1833)
No Z-drug, proximal GP
consultation (n = 10,214)
Benzodiazepine
(n = 5172)
Fracture
Incidence rate per 100PY (events) 11.4 (164) 7.6 (130) 8.4 (269) 12.5 (223)
Age, sex-adjusted HR (95% CI) NA 1.39 (1.08–1.78) 1.40 (1.14–1.70) 0.93 (0.76–1.14)
Fully adjusted HR (95% CI)a NA 1.32 (0.99–1.75) 1.34 (1.08–1.67)b 0.99 (0.80–1.23)
Hip fracture
Incidence rate per 100PY (events) 5.7 (84) 3.4 (60) 3.5 (115) 5.1 (94)
Age, sex-adjusted HR (95% CI) NA 1.53 (1.07–2.18) 1.64 (1.23–2.19) 1.11 (0.82–1.49)
Fully adjusted HR (95% CI)a NA 1.38 (0.92–2.06) 1.59 (1.15–2.19)b 1.10 (0.87–1.65)
Forearm/wrist/hand fracture
Incidence rate per 100PY (events) 2.0 (29) 1.1 (20) 1.5 (48) 2.5 (46)
Age, sex-adjusted HR (95% CI) NA 1.80 (0.95–3.41) 1.35 (0.85–2.14) 0.81 (0.51–1.28)
Fully adjusted HR (95% CI)a NA 1.44 (0.60–3.47) 1.33 (0.77–2.31) 1.00 (0.59–1.70)
Fall
Incidence rate per 100PY (events) 37.1 (473) 27.3 (384) 25.8 (767) 35.8 (585)
Age, sex-adjusted HR (95% CI) NA 1.12 (0.97–1.29) 1.52 (1.36–1.71) 1.06 (0.94–1.20)
Fully adjusted HR (95% CI)a NA 1.02 (0.87–1.21) 1.43 (1.26–1.62)b 1.08 (0.95–1.22)
Mortality
Incidence rate per 100PY (events) 28.4 (436) 16.7 (301) 24.1 (799) 39.0 (736)
Age, sex-adjusted HR (95% CI) NA 1.51 (1.29–1.77) 1.20 (1.06–1.34) 0.72 (0.64–0.81)
Fully adjusted HR (95% CI)a NA 1.38 (1.14–1.66)b 1.08 (0.94–1.23) 0.73 (0.64–0.83)b
Acute bacterial infection
Incidence rate per 100PY (events) 47.8 (416) 43.6 (220) 40.6 (1325) 57.8 (371)
Age, sex-adjusted HR (95% CI) NA 1.13 (0.94–1.37) 1.24 (1.09–1.42) 1.01 (0.86–1.18)
Fully adjusted HR (95% CI)a NA 1.02 (0.82–1.27) 1.13 (0.98–1.31) 0.92 (0.78–1.10)
Ischaemic stroke/transient ischaemic attack
Incidence rate per 100PY (events) 6.2 (93) 4.4 (77) 5.5 (178) 6.0 (110)
Age, sex-adjusted HR (95% CI) NA 1.32 (0.95–1.83) 1.20 (0.94–1.54) 1.03 (0.78–1.36)
Fully adjusted HR (95% CI)a NA 1.35 (0.90–2.04) 1.14 (0.86–1.50) 1.05 (0.78–1.43)
Venous thromboembolism
Incidence rate per 100PY (events) 1.5 (22) 1.3 (21) 1.4 (43) 2.5 (47)
Age, sex-adjusted HR (95% CI) NA 1.64 (0.97–2.79) 1.14 (0.74–1.76) 0.79 (0.50–1.25)
Fully adjusted HR (95% CI)a NA 1.65 (0.74–3.69)c 1.12 (0.67–1.85) 0.82 (0.50–1.34)
Abbreviations: HR hazard ratio, CI confidence interval, GP general practitioner, PY person-years
aAdjusted for all covariates listed in Table 1
bFully adjusted HR remaining statistically significant after controlling the false discovery rate to < 5% (based on 13 outcomes)
cNot adjusted for antiepileptics, antiplatelet drugs, pneumonia vaccine, and anxiety symptoms due to model instability
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mortality, infection, or venous thromboembolism with
Z-drug use. PlwD prescribed higher dose Z-drugs were
also more likely to be admitted to hospital, visit their
GP, and be further prescribed antipsychotics, antidepres-
sants, and antibiotics.
We designed the study to minimise possible sources of
bias [34]. Although we were unable to measure dementia
severity, we adjusted for the duration since the dementia
diagnosis, prescription of dementia medications and an-
tipsychotics, history of agitation/psychosis, and end of
life care. However, there may be residual confounding
by dementia severity for some comparisons. Although
underlying severity was unclear, the mortality results
suggest that, compared to Z-drug users, the sleep
Table 3 Adjusted hazard ratios for Z-drug prescription and adverse events for people with dementia according to prescribed daily
defined dose of Z-drugs
Outcome
and daily
defined
dose
prescribeda
No.
events
in the
Z-drug
cohort
Sleep disturbance and no sedative-hypnotic (n = 1833) No Z-drug, proximal GP consultation (n = 10,214)
Age, sex adjusted Fully adjustedb Age, sex adjusted Fully adjustedb
Fracture
≤ 0.5 117 1.30 (0.99–1.70) 1.22 (0.90–1.66) 1.33 (1.07–1.65) 1.28 (1.01–1.63)
0.6–0.9 5 1.28 (0.51–3.20) 1.06 (0.39–2.89) 1.24 (0.50–3.05) 1.08 (0.42–2.76)
≥ 1 42 1.70 (1.19–2.42) 1.67 (1.13–2.46)c 1.66 (1.18–2.34) 1.58 (1.09–2.28)c
Hip fracture
≤ 0.5 55 1.30 (0.88–1.93) 1.21 (0.78–1.90) 1.42 (1.03–1.97) 1.43 (1.00–2.06)
0.6–0.9 < 5 1.10 (0.26–4.67) 0.79 (0.15–4.11) 1.27 (0.31–5.22) 1.05 (0.24–4.64)
≥ 1 27 2.30 (1.45–3.65) 1.96 (1.16–3.31)c 2.50 (1.61–3.89) 2.36 (1.44–3.87)c
Forearm fracture
≤ 0.5 20 1.66 (0.81–3.40) 1.22 (0.48–3.12) 1.28 (0.77–2.15) 1.29 (0.73–2.27)
≥ 0.6 9 2.18 (0.98–4.85) 1.91 (0.67–5.47) 1.53 (0.72–3.24) 1.42 (0.59–3.38)
Fall
≤ 0.5 335 1.05 (0.90–1.22) 0.95 (0.80–1.13) 1.43 (1.26–1.63) 1.35 (1.17–1.56)c
0.6–0.9 14 0.84 (0.49–1.44) 0.73 (0.41–1.29) 1.19 (0.70–2.02) 1.07 (0.61–1.87)
≥ 1 124 1.42 (1.15–1.74) 1.33 (1.06–1.66)c 1.92 (1.58–2.35) 1.81 (1.46–2.34)c
Mortality
≤ 0.5 321 1.49 (1.26–1.77) 1.38 (1.14–1.68)c 1.18 (1.03–1.34) 1.07 (0.93–1.24)
0.6–0.9 16 1.56 (0.95–2.56) 1.60 (0.96–2.70) 1.25 (0.77–2.02) 1.22 (0.75–1.99)
≥ 1 99 1.56 (1.24–1.96) 1.33 (1.03–1.71) 1.26 (1.02–1.55) 1.06 (0.85–1.33)
Acute bacterial infection
≤ 0.5 297 1.15 (0.98–1.36) 1.00 (0.83–1.20) 1.37 (1.20–1.57) 1.23 (1.06–1.43)c
0.6–0.9 13 0.98 (0.56–1.72) 0.86 (0.47–1.57) 1.20 (0.69–2.08) 1.12 (0.63–1.99)
≥ 1 106 1.40 (1.12–1.76) 1.25 (0.98–1.60) 1.64 (1.32–2.04) 1.52 (1.21–1.91)c
Ischaemic stroke/transient ischaemic attack
≤ 0.5 55 1.04 (0.72–1.51) 1.12 (0.71–1.75) 0.96 (0.71–1.30) 0.95 (0.68–1.31)
0.6–0.9 5 1.97 (0.78–4.96) 1.98 (0.74–5.28) 1.74 (0.72–4.19) 1.71 (0.74–3.98)
≥ 1 33 2.07 (1.36–3.15) 1.88 (1.14–3.10)c 1.90 (1.30–2.79) 1.61 (1.08–2.42)
Venous thromboembolism
≤ 0.5 26 2.01 (1.16–3.49) 2.00 (0.90–4.47) 1.35 (0.85–2.13) 1.26 (0.74–2.12)
≥ 0.6 < 5 0.78 (0.27–2.25) 0.85 (0.21–3.39) 0.56 (0.21–1.54) 0.66 (0.22–1.95)
Abbreviations: HR hazard ratio, CI confidence interval, GP general practitioner
aThe reference group for all comparisons is no Z-drug prescription. Most patients assigned to the ‘0.6–0.9 DDD’ Z-drug group were prescribed 3.75 mg zopiclone
with instructions similar to ‘TAKE ONE OR TWO AT NIGHT’
bAdjusted for all covariates listed in Table 1
cFully adjusted HR remaining statistically significant after controlling the false discovery rate to < 5% (based on 37 tests; 11 outcomes with three dose categories
and two outcomes with two dose categories)
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disturbance group not prescribed sedatives may have less
severe dementia, however that the non-users with prox-
imal GP consultation had comparable dementia severity.
Residual confounding by sleep disturbance severity is
also a possibility. Sleep disturbance was challenging to
identify within the electronic primary care record as
highlighted in our validation study, where only 42% of
our selected ‘sleep disturbance’ patients had sleep dis-
turbance confirmed by their GP practice. This could be
partly due to the sometimes contradictory ‘sleep pattern’
records or that the sleep disturbance recorded was
transient or due to other causes, such as urinary incon-
tinence or alcohol abuse. The comparable fall risk in the
Z-drug and ‘sleep disturbance’ group could be due to
urinary incontinence and alcohol use being more com-
mon in the ‘sleep disturbance’ group. The coding of
‘sleep disturbance’ was often vague and may represent
conditions other than insomnia. It may be that some of
the ‘sleep disturbance and no sedative’ group had milder
cases of sleep disturbance than those prescribed Z-
drugs. Performing a sensitivity analysis on the sleep dis-
turbance definition reduced our effects slightly. Residual
Table 4 Adjusted hazard and rate ratios for new Z-drug prescription and new prescriptions, GP consultations, and hospital
admissions for people with dementia
Outcome Comparator
Z-drug
(n = 3532)
Sleep disturbance, no sedative-
hypnotic (n = 1833)
No Z-drug, proximal GP consultation
(n = 10,214)
Benzodiazepine
(n = 5172)
Number of hospital admissions
Rate per 100PY (events) 126.7
(1944)
93.0 (1671) 107.7 (3563) 129.4 (2441)
Age, sex-adjusted RR
(95% CI)
NA 1.34 (1.20–1.49) 1.26 (1.15–1.39) 0.98 (0.89–1.09)
Fully adjusted RR (95%
CI)a
NA 1.26 (1.13–1.40)b 1.17 (1.07–1.27)b 0.92 (0.84–1.01)
Number of GP consultations
Rate per 100PY (events) 1387.8
(21292)
1124.6 (20209) 1511.7 (50021) 1502.6 (28335)
Age, sex-adjusted RR
(95% CI)
NA 1.29 (1.22–1.37) 0.97 (0.93–1.01) 0.94 (0.90–0.98)
Fully adjusted RR (95%
CI)a
NA 1.17 (1.12–1.23)b 1.07 (1.04–1.11)b 0.96 (0.93–1.00)
New antipsychotic prescription
Incidence rate per 100PY
(events)
38.7 (331) 10.3 (130) 15.2 (227) 75.4 (532)
Age, sex-adjusted HR
(95% CI)
NA 2.53 (2.03–3.14) 3.68 (3.10–4.37) 0.79 (0.68–0.90)
Fully adjusted HR (95%
CI)a
NA 2.37 (1.84–3.04)b 3.85 (3.18–4.65)b 0.86 (0.74–0.99)
New antidepressant prescription
Incidence rate per 100PY
(events)
23.8 (172) 8.2 (82) 10.3 (199) 30.3 (242)
Age, sex-adjusted HR
(95% CI)
NA 2.24 (1.70–2.94) 2.52 (2.05–3.10) 0.86 (0.71–1.05)
Fully adjusted HR (95%
CI)a
NA 2.32 (1.65–3.25)b 2.65 (2.09–3.37)b 0.88 (0.71–1.10)
New antibiotic prescription
Incidence rate per 100PY
(events)
109.1 (791) 61.2 (517) 89.5 (1738) 111.0 (1096)
Age, sex-adjusted HR
(95% CI)
NA 1.46 (1.30–1.65) 1.27 (1.17–1.38) 1.01 (0.92–1.10)
Fully adjusted HR (95%
CI)a
NA 1.34 (1.17–1.52)b 1.19 (1.08–1.30)b 1.05 (0.95–1.15)
Abbreviations: HR hazard ratio, CI confidence interval, PY person-years, RR rate ratio
aAdjusted for all covariates listed in Table 1
bFully adjusted HR remaining statistically significant after controlling the false discovery rate to < 5% (based on 13 outcomes)
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confounding by severity of insomnia or dementia could
also affect the associations with higher Z-drug doses.
We also had no data on genetic information and envir-
onmental factors, which may influence fall risk in people
living with dementia [35]. There was likely some small
residual confounding due to new admission to a care
home; however, we were unable to accurately ascertain
the admission date to control for this.
Our study was strengthened by additional comparisons
to non-users with a proximal GP visit and new benzodi-
azepine users. As benzodiazepines are also prescribed for
anxiety and behavioural disturbances of dementia, there
may be residual confounding by dementia and sleep dis-
turbance severity in the comparison between Z-drug and
benzodiazepine users. However, when instead restricting to
benzodiazepines likely prescribed for sleep disturbance, our
findings were very similar. Dosing instructions were often
missing for benzodiazepines, and although we made
plausible assumptions based on the complete prescriptions,
some misclassification of exposures is possible. Recording
of prescriptions issued in primary care is accurate; however,
we lacked data on medications prescribed in secondary care
or obtained elsewhere. Medication adherence is unknown;
therefore, the Z-drug effects may be underestimated if
many patients prescribed Z-drugs had not taken them.
Studies report high positive predictive values for patients
coded with our study outcomes in UK primary care data
[36–41]. Potential under-reporting in CPRD was improved
through linkage to HES and ONS. However, we likely
underestimated forearm fracture incidence as many do not
require hospital admission. Similarly, GP records of falls
may under-represent all falls that occur in the older popula-
tion, but more accurately represent ‘injurious falls requiring
medical attention’ [42]. Our study was strengthened by
using a new-user design and careful selection and follow-
up of patients taking Z-drugs alone and not concurrent
Table 5 Adjusted hazard ratios for Z-drug prescription and new prescriptions, GP consultations, and hospital admissions for people
with dementia according to prescribed daily defined doses (DDDs) of Z-drugs
Outcome
and daily
defined
dose
prescribeda
No.
events
in the
Z-drug
cohort
No sedative-hypnotic, sleep disturbance (n = 1833) No Z-drug, proximal GP consultation (n = 10,214)
Age, sex adjusted Fully adjustedb Age, sex adjusted Fully adjustedb
Number of hospital admissionsc
≤ 0.5 1403 1.24 (1.10–1.39) 1.18 (1.05–1.32) 1.19 (1.07–1.31) 1.10 (1.00–1.20)
0.6–0.9 63 1.06 (0.76–1.49) 1.22 (0.88–1.69) 1.03 (0.74–1.43) 1.10 (0.80–1.51)
≥ 1 472 1.35 (1.15–1.58) 1.29 (1.10–1.50)d 1.32 (1.15–1.52) 1.22 (1.06–1.39)d
Number of GP consultationsc
≤ 0.5 9230 1.21 (1.14–1.29) 1.10 (1.05–1.16)d 0.89 (0.85–0.94) 1.00 (0.96–1.04)
0.6–0.9 690 1.12 (0.96–1.32) 1.10 (0.95–1.26) 0.83 (0.71–0.97) 1.02 (0.88–1.17)
≥ 1 4823 1.23 (1.12–1.34) 1.16 (1.08–1.25)d 0.91 (0.84–0.98) 1.06 (0.99–1.13)
Incident antipsychotic prescription
≤ 0.5 214 2.08 (1.64–2.62) 2.00 (1.54–2.61)d 3.09 (2.56–3.74) 3.31 (2.69–4.07)d
0.6–0.9 18 3.35 (2.04–5.50) 2.75 (1.57–4.81)d 5.15 (3.19–8.32) 4.82 (2.81–8.25)d
≥ 1 99 4.05 (3.10–5.31) 3.56 (2.61–4.85)d 5.81 (4.55–7.42) 5.82 (4.44–7.63)d
Incident antidepressant prescription
≤ 0.5 124 1.25 (1.14–1.37) 1.16 (1.05–1.28)d 2.47 (1.91–3.19) 2.39 (1.90–2.99)d
0.6–0.9 8 1.20 (0.83–1.73) 1.13 (0.76–1.68) 2.67 (1.19–5.99) 3.00 (1.49–6.01)
≥ 1 40 1.37 (1.17–1.61) 1.31 (1.11–1.54)d 3.47 (2.32–5.18) 2.93 (2.04–4.19)d
Incident antibiotic prescription
≤ 0.5 583 1.43 (1.27–1.63) 1.30 (1.13–1.49)d 1.25 (1.14–1.37) 1.16 (1.05–1.28)d
0.6–0.9 27 1.36 (0.93–2.00) 1.20 (0.79–1.81) 1.20 (0.83–1.73) 1.13 (0.76–1.68)
≥ 1 181 1.57 (1.32–1.88) 1.46 (1.21–1.76)d 1.37 (1.17–1.61) 1.31 (1.11–1.54)d
Abbreviations: HR hazard ratio, CI confidence interval, GP general practitioner
aThe reference group for all comparisons is no Z-drug prescription. Most patients assigned to the ‘0.6–0.9 DDD’ Z-drug group were prescribed 3.75 mg zopiclone
with instructions similar to ‘TAKE ONE OR TWO AT NIGHT’
bAdjusted for all covariates listed in Table 1
cEstimates provided are rate ratios (95% confidence intervals)
dFully adjusted HR remaining statistically significant after controlling the false discovery rate to < 5% (based on 37 tests; 11 outcomes with three dose categories
and two outcomes with two dose categories)
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with other sedative-hypnotics [43, 44]. Our findings are
generalizable to most people with diagnosed dementia and
sleep disturbance. Few patients were prescribed zaleplon or
zolpidem and none eszopiclone; however, as they exert the
same pharmacological action as zopiclone, the adverse ef-
fects of these agents are likely similar.
Comparison with other studies
Fractures
Few studies have examined Z-drug dose and fracture
risk. Greater risks of hip fracture were reported among
older US care home residents taking higher dose Z-
drugs, although limited by small numbers [45]. Add-
itionally, few studies have examined fracture risk in
PlwD taking Z-drugs. Consistent with our findings, a
study of hospital records of PlwD in Japan reported in-
creased fracture risks with Z-drug use, but they were un-
able to ascertain whether the prescription was given
before or after the fracture [46]. Various studies report
associations between Z-drugs and fracture risk, and spe-
cifically hip fracture risk, in older adults [12, 13]. How-
ever, our study and others suggest this relative risk is
lower in PlwD [47, 48]. For example, in US nursing
home residents, greater odds ratios were estimated be-
tween non-benzodiazepine hypnotic drug use and hip
fracture in residents with no or only mild cognitive im-
pairment than with moderate-severe cognitive impair-
ment [47]. Z-drugs likely increase fracture risk through
their effects on gait and balance [49, 50]. A randomised
trial reported more tandem walk failures upon night-
time awakening among older adults randomised to 5 mg
zolpidem compared to placebo [51].
Falls
Z-drugs were originally claimed to cause fewer falls than
benzodiazepines [52]; however, we found similar or lar-
ger effects. This is consistent with findings from older
men in the Osteoporotic Fractures in Men study [53].
More fall-related injuries were observed with Z-drug use
in older people in Taiwan, with greater frequencies when
prescribed > 0.6 DDDs [54]. Increased fall rates have also
been observed with dose increases in sedative-hypnotics
in nursing home residents with dementia [55].
Cardiovascular outcomes
Similar to us, more strokes were observed in the
Medicine use and Alzheimer’s disease (MEDALZ) cohort
prescribed Z-drugs and adults in Taiwan prescribed zol-
pidem [15, 56]. Unfortunately, neither study estimated
dose-specific risks. Mechanisms for Z-drugs causing in-
creased stroke risk are uncertain, but could relate to de-
creased local cerebral blood flow [56]. However, as
prolonged sleep disturbances likely increase stroke risk,
residual confounding by sleep disturbance severity and
duration could underlie reported associations [57].
Infections
Analysis of RCT data, generally in younger adults, indi-
cated possible 1.5–2-fold increased infection risks when
taking zopiclone and zolpidem [58]. We found inconsist-
ent evidence of increased bacterial infection risk with
higher dose Z-drugs. Other studies in older adults, in-
cluding a MEDALZ cohort study, report no association
between Z-drug use and risk of pneumonia [59–61]. To-
gether, these suggest that if acute infection risk increases
with higher dose Z-drug use in PlwD, then it is likely to
be small, and our study was underpowered to detect it.
Mortality
Consistent with our findings, a MEDALZ cohort study
found benzodiazepine use associated with increased
mortality, but not Z-drugs [62]. Studies on Z-drug or
benzodiazepine use and mortality in adults have been
conflicting, and reported associations may simply stem
from increased usage of benzodiazepines with ap-
proaching death [63].
Healthcare utilisation
We observed greater subsequent initiation of antipsy-
chotics and antidepressants among Z-drug users, simi-
larly observed by older people prescribed Z-drugs in a
Taiwan study [54]. This likely reflects the increased be-
havioural and psychological symptoms of dementia as it
progresses. The increased hospital visits we observed
post-Z-drug initiation could partly reflect the increased
fracture and stroke rates in these patients. The Taiwan
study also reported greater rates of fall-related injuries
requiring hospitalisation among Z-drug users [54].
Conclusions
Higher doses of Z-drugs should be avoided in PlwD due
to increased fracture and stroke risks. One in six PlwD
in our study was commenced at 7.5 mg zopiclone or
equivalent daily. Prescribers should use the lowest effect-
ive dose in the elderly and use simple specific drug regi-
mens, and this advice needs implementing in national
guidelines [64, 65]. Our findings suggest that the safety
profile of Z-drugs should be considered similar to ben-
zodiazepines in PlwD. Although the risks associated with
low-dose Z-drugs were small, as the effectiveness of Z-
drugs is also unproven in dementia, we advise adhering
to the Beers criteria guidelines of avoiding Z-drug use in
PlwD, where possible [66]. Alternative strategies should
be sought for sleep disturbance other than Z-drug or
benzodiazepine dose escalation. Where pharmacological
management of sleep disturbance is initiated, fracture
risk management plans are implemented, and
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prescriptions regularly reviewed to mitigate potential ad-
verse health outcomes. This gives a clear and important
steer for the use of hypnotics in people with dementia in
clinical practice. This evidence is currently particularly
important as social isolation related to the COVID-19
pandemic may increase the frequency of neuropsychi-
atric symptoms in dementia [67] and limit resources to
offer non-pharmacological management approaches.
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